News articles about Iovance Biotherapeutics (NASDAQ:IOVA) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.4211024560548 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- 4 Small Speculative Names on My Radar (finance.yahoo.com)
- Iovance Biotherapeutics (IOVA) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS (americanbankingnews.com)
- Iovance Biotherapeutics (IOVA) Lowered to “Hold” at BidaskClub (americanbankingnews.com)
- Iovance Biotherapeutics (IOVA) PT Raised to $24.00 at B. Riley (americanbankingnews.com)
- RXi partners with Calif. firm on cancer treatment research (wbjournal.com)
Shares of Iovance Biotherapeutics opened at $16.45 on Thursday, Marketbeat Ratings reports. The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -11.67 and a beta of 5.94. Iovance Biotherapeutics has a 52 week low of $15.20 and a 52 week high of $16.50.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.02). equities research analysts forecast that Iovance Biotherapeutics will post -1.27 earnings per share for the current fiscal year.
Several equities analysts have commented on the stock. B. Riley raised their price target on shares of Iovance Biotherapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, May 11th. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Iovance Biotherapeutics in a research report on Friday, May 11th. BidaskClub cut shares of Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 11th. Finally, ValuEngine raised shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Iovance Biotherapeutics currently has an average rating of “Buy” and a consensus target price of $20.81.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.